Form 4: Viatris CCO's Equity Transactions Post RSU Vesting

Viatris Chief Commercial Officer Corinne Le Goff reported the vesting of restricted stock units and dividend equivalent units, alongside associated tax-related share dispositions.

Summary

• Corinne Le Goff, Chief Commercial Officer of Viatris Inc. (VTRS), reported transactions related to her equity holdings.
• On March 4, 2026, 36,720 Restricted Stock Units (RSUs) granted on April 18, 2024, vested and settled into common stock.
• Concurrently, 3,053 Dividend Equivalent Units (DEUs) that accrued on these RSUs also vested and settled into common stock.
• To cover tax liabilities associated with the RSU vesting, 16,300 shares of common stock were withheld and disposed of at a price of $14.71 per share.
• An additional 1,355 shares of common stock were withheld and disposed of at $14.71 per share to cover tax liabilities from the DEU vesting.
• Following these transactions, Corinne Le Goff beneficially owns 57,417 shares of Viatris common stock directly.
• She also beneficially owns 36,721 unvested Restricted Stock Units and 3,053 unvested Dividend Equivalent Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the routine vesting of executive compensation and alignment of interests, with no new strategic or operational information.

Positives

• Vesting of RSUs and DEUs indicates long-term incentive plans are maturing, aligning management interests with shareholders.
• The acquisition of shares at $0 price reflects compensation through equity awards, a common practice for executive retention and motivation.

Negatives

• Disposition of shares for tax purposes reduces the officer's direct equity stake, though this is a standard practice for equity compensation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity compensation, particularly through RSUs and DEUs, is a standard practice across the pharmaceutical and healthcare industries to attract, retain, and incentivize key executives. The vesting schedule aligns executive interests with long-term company performance, a common governance strategy.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Dividend Equivalent Units (DEUs) for executive compensation is a widely adopted practice, comparable to compensation structures at peer companies like Pfizer, Teva Pharmaceutical, and Bristol Myers Squibb.
• The disposition of shares to cover tax liabilities upon vesting is a standard and expected event for equity awards, reflecting common tax planning for executives receiving such compensation.

Stakeholder Impact

• Shareholders: Minor dilution from share issuance (though offset by tax withholding), but primarily signals continued executive alignment with company performance through equity ownership.
• Employees: No direct impact on general employees.
• Management: Corinne Le Goff's equity stake changes, reflecting the realization of compensation and continued incentive.

Next Steps

• Vesting of the remaining 36,721 Restricted Stock Units on March 4, 2027.

Key Dates

Recommendation

This Form 4 details routine executive compensation vesting and associated tax-related share dispositions. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and reflect standard executive incentive plans.

Keywords

Viatris, VTRS, Form 4, insider trading, equity compensation, restricted stock units, dividend equivalent units, executive compensation, stock vesting, share disposition